Yulia Slavina

Tyra Biosciences publishes new research on FGFR3-selective inhibitors for urologic cancers and achondroplasia

Tyra Biosciences publishes new research on FGFR3-selective inhibitors for urologic cancers and achondroplasia
Tyra Biosciences releases FGFR3 study

Tyra Biosciences announced the publication of a new scientific paper in the Journal of Medicinal Chemistry examining the biology, molecular design, and therapeutic implications of FGFR3-selective inhibitors in the treatment of urologic cancers and achondroplasia.

The company shared the development as part of its ongoing research efforts in targeted therapy, focusing on advancing the understanding of inhibitors that may have future clinical applications.

Tyra Biosciences has previously advanced therapies targeting FGFR3 to address achondroplasia and select urologic cancers, according to an earlier update on its research efforts. The company highlighted progress in FGFR3-driven treatment strategies. These initiatives form part of its ongoing focus on next-generation targeted therapies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.